Navigation Links
OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
Date:3/11/2009

nts that could be deemed forward-looking statements.

The potential risks and uncertainties associated with forward-looking statements include, among others, the possibility that an agreement with the FDA cannot be reached regarding a clinical trial using pain as the primary endpoint for OGX-011, the timing and costs of clinical trials and regulatory approvals, risks that clinical trials will not be successful or confirm earlier or interim clinical trial results, the Company's need for additional financing, the uncertainty associated with any potential partnering discussions, risks relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products and the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for fiscal year 2008. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or that if any of them do transpire or occur, what impact they would have on the results of operations or financial condition of the Company. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.

               Condensed Consolidated Statements of Operations
                               (in thousands)

                                    Three Months Ended        Year Ended
                                       December 31,          December 31,
                                       2008       2007       2008       2007
                                       (unaudited)
    Operating expenses
      Research and development     $  4,198   $  1,060   $  7,819   $  4,135
      General and administrative      1,050        831      3,293      3,540
                                   --------------------  --------------------
    Total oper
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... AUSTIN, Texas , Dec. 24, 2014  Vermillion, ... focused on gynecologic disease, announced today that the ... investors including Oracle Investment Management, Jack W. ... directors. Total proceeds were $10.5 million, before offering ...
(Date:12/24/2014)... December 23, 2014 GMO corn cases filed ... are in the process of being consolidated in a Kansas ... Re: Syngenta AG MIR 162 Corn Litigation, MDL No. 2591 ... , Management of the Syngenta GMO corn multidistrict litigation (MDL) ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 On Friday, ... 83, the Omnibus and Continuing Resolution Appropriations Act of ... condition eligible to receive funding through the Congressionally Directed ... Defense (DoD). The Hydrocephalus Association (HA), working in conjunction ...
(Date:12/24/2014)... Nashville, Tenn. (PRWEB) December 23, 2014 Nashville ... was elected treasurer for the American Society for Reproductive Medicine ... research in reproductive medicine. In his new role as ... board and will have a voice in furthering the mission ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3
... - These are not your parents' generation of corporate ... rarely heard to cross the lips of gray-haired, gray-suited ... problem is that Wisconsin doesn't yet have it. , ... of business, civic, academic and arts groups met to ...
... General Electric Co.'s GE Healthcare division rose 17 ... in total orders, the company reported Friday. , ,GE Healthcare ... -- reported revenue of $3.6 billion for the second quarter, ... period a year ago. , ,Profits for GE Healthcare rose ...
... private colleges and universities in Wisconsin will work toward ... Jenzabar, Inc. of Cambridge, Mass. , ,Jenzabar ... Association of Independent Colleges and Universities to use ... EX ERP System, Jenzabar's Internet Campus Solution and Jenzabar's ...
Cached Biology Technology:Tech leaders call for more creativity 2
(Date:12/22/2014)... and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ) has ... Watermarking and Fingerprinting Markets" report to their ... This insight provides an overview of ... Watermarking aims to control and monitor piracy by ...
(Date:12/19/2014)... and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) has announced the ... Security Systems Market" report to their offering. ... perimeter security market is estimated to grow at a CAGR ... holds a larger share in this market, Canada ...
(Date:12/17/2014)... Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) has announced the ... Button Synaptics Fingerprint Sensor Technology Analysis" report to ... Based on a totally different sensing technology ... time a fingerprint sensor in its product. ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... keeps urchin populations in check, allowing kelp a favorite ... were harvested to near extinction for their fur? The resulting ... food or shelter for fish and invertebrates. And so it ... affect others. Such is the potential trickle-down effect on ...
... imposed a ban on importing foreign ash trees in order ... the trees and has entered the country via imports from ... trade, horticultural stakeholders and the plant buying public need to ... by imported plant pathogens. They say it is far better ...
... the on-line publication by the European Journal of Human ... led by Dr. Robert Cook-Degan, a former member of the ... of the BRCA1/2 genetic test in the US, has amassed ... Cornel, chair of the European Society of Human Genetics, Professional ...
Cached Biology News:New study to examine ecological tipping points in hopes of preventing them 2New study to examine ecological tipping points in hopes of preventing them 3Action needed to prevent more devastating tree diseases entering the UK 2Privately owned genetic databases may hinder diagnosis and bar the way to the arrival of personalized medicine 2
Guanylate Kinase Purified Anti-Mouse, Anti-Rat clone 28, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
...
Proliferin (C-14)...
... The Turn & Cast submarine gel systems used gasketed ... the gel in the tank. Turn it back and ... For added convenience, each Turn & Cast tray is ... near the edge of the tray and one in ...
Biology Products: